Novo Nordisk and Oxford University team up to develop novel treatments

Novo NordiskToday, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.

"We are excited to have this chance to further develop our autoimmune inflammatory disease pipeline in close collaboration with such a world-class translational research centre as the Kennedy Institute of Rheumatology," says Per Falk, senior vice president of the Biopharmaceutical Research Unit at Novo Nordisk.

"The overall ambition is to combine our companys clinical development strengths with those of the Kennedy Institute to increase the odds that we can successfully develop novel treatment regimens and get them more quickly to the patients who could potentially benefit from them," adds Per Falk.

The Kennedy Institute of Rheumatology is renowned for having made breakthroughs in the understanding of the biological pathways that lead to rheumatoid arthritis, which has had a major impact on the treatment of autoimmune inflammatory disease. Professor Sir Marc Feldmann, Head of the Institute, together with his colleague Sir Ravinder Maini, discovered the efficacy of anti-tumour necrosis factor or anti-TNF treatment, a class of drugs used as the current standard of care for moderate-to-severe rheumatoid arthritis and other autoimmune inflammatory diseases.

The Institute focuses on translational research techniques, including the novel use of diseased human tissue to validate new drug targets as tractable avenues for the treatment of autoimmune inflammatory diseases, and also the identification of specific biomarkers of disease that can be used to evaluate the effectiveness of new interventions in a range of patient populations.

"As a translational research centre, we are keen to do clinical research on truly innovative ideas that have the potential to improve how patients with autoimmune inflammatory disease are treated today," says Professor Feldmann. "Despite advances, there is still a considerable unmet need in this area with many of the patients responding only partially to existing treatments. The need for new therapeutic options is imperative."

"We will work closely together with Novo Nordisk to apply the most advanced translational research approaches available for discovering new mechanisms and validating drug targets and candidates in autoimmune inflammatory disease in a variety of human disease tissue types and at different stages of disease to ensure comprehensive characterisation of each compound's clinical potential," adds Professor Feldmann.

Novo Nordisk will fund 10 Oxford researchers at the Kennedy Institute of Rheumatology to work within the partnership. A Joint steering committee with members from both parties, including Per Falk and Professor Feldmann, will oversee the partnership and assess research proposals from scientists at both organisations.

About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that can affect many tissues and organs, but principally attacks the joints. It is prevalent in about 1% of the world's population. Since, RA can present very differently in diverse patient groups, it is often necessary to evaluate the effectiveness of new RA treatments in a variety of patient populations, as well as at various stages of disease development in order to optimally identify in which patient group the new treatment is most likely to be effective.

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]